← All trials
NCT05766631
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2023
- Primary completion
- Jun 30, 2027
- Completion date
- Sep 29, 2027
- First posted
- Mar 13, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Friends Research Institute, Inc.Lead sponsor
- Friends Research Institute, Inc.Overall official - principal investigator
- National Institute on Drug Abuse (NIDA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.